Original Research
Published on 02 Jun 2022
Key Considerations for Phase 2 or 3 Clinical Study Design of Anti-Inflammatory Agent for COVID-19 Treatment
in Translational Pharmacology
Frontiers in Pharmacology
doi 10.3389/fphar.2022.842836
- 2,590 views





